The PI3k pathway represents an attractive target for drug development in melanoma, as numerous studies have
shown that this pathway is active in malignant melanocytes. In addition, previous work has shown that multi-level
targeting of this pathway might be more effective than targeting the pathway at a single level. In this review, we discuss
targeting different members of this pathway, potential escape mechanisms, classes of specific molecular inhibitors, and
development of NVP-BEZ235, a novel dual PI3k/mTOR inhibitor.